Clinical trial
RFT-5-dgA in Patients With Metastatic Melanoma
NCT00314093 · University of Texas Southwestern Medical Center, Other · Completed
Key facts
| NCT number | NCT00314093 |
|---|---|
| Title | RFT-5-dgA in Patients With Metastatic Melanoma |
| Official title | Phase II Evaluation of RFT5-dgA in Patients With Metastatic Melanoma |
| Lead sponsor | University of Texas Southwestern Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | RFT5pdgA |
| Enrollment | 41 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Apr 12, 2006 |
| Last update posted | Nov 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: